anti arid2  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti arid2
    <t>ARID2</t> is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.
    Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer"

    Article Title: HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer

    Journal: International Journal of Biological Sciences

    doi: 10.7150/ijbs.38146

    ARID2 is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.
    Figure Legend Snippet: ARID2 is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.

    Techniques Used: Quantitative RT-PCR, Western Blot, Expressing, Binding Assay, Luciferase, Activity Assay, Migration, Transfection

    Exosomal miR-155-5p promotes cervical cancer progression via the ARID2-ERCC5-NF-κB signaling axis. (A) Volcano plot analysis of differentially expressed genes (fold change > 4; P < 0.05) after ARID2 knockdown. (B) Pathway network of differentially expressed genes. (C) Coexpression network of differentially expressed genes. (D) Immunoblotting assays of the indicated proteins in CaSki cells with the indicated treatments. (E, F) We used molecular docking to predict whether ARID2 and ERCC5 could bind. The predicted results show that ARID2 and ERCC5 bound by multiple potential interactions. Furthermore, we determined that ARID2 and ERCC5 bind to each other in cells by co-IP experiments.
    Figure Legend Snippet: Exosomal miR-155-5p promotes cervical cancer progression via the ARID2-ERCC5-NF-κB signaling axis. (A) Volcano plot analysis of differentially expressed genes (fold change > 4; P < 0.05) after ARID2 knockdown. (B) Pathway network of differentially expressed genes. (C) Coexpression network of differentially expressed genes. (D) Immunoblotting assays of the indicated proteins in CaSki cells with the indicated treatments. (E, F) We used molecular docking to predict whether ARID2 and ERCC5 could bind. The predicted results show that ARID2 and ERCC5 bound by multiple potential interactions. Furthermore, we determined that ARID2 and ERCC5 bind to each other in cells by co-IP experiments.

    Techniques Used: Western Blot, Co-Immunoprecipitation Assay

    anti arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti arid2
    <t>ARID2</t> is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.
    Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer"

    Article Title: HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer

    Journal: International Journal of Biological Sciences

    doi: 10.7150/ijbs.38146

    ARID2 is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.
    Figure Legend Snippet: ARID2 is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.

    Techniques Used: Quantitative RT-PCR, Western Blot, Expressing, Binding Assay, Luciferase, Activity Assay, Migration, Transfection

    Exosomal miR-155-5p promotes cervical cancer progression via the ARID2-ERCC5-NF-κB signaling axis. (A) Volcano plot analysis of differentially expressed genes (fold change > 4; P < 0.05) after ARID2 knockdown. (B) Pathway network of differentially expressed genes. (C) Coexpression network of differentially expressed genes. (D) Immunoblotting assays of the indicated proteins in CaSki cells with the indicated treatments. (E, F) We used molecular docking to predict whether ARID2 and ERCC5 could bind. The predicted results show that ARID2 and ERCC5 bound by multiple potential interactions. Furthermore, we determined that ARID2 and ERCC5 bind to each other in cells by co-IP experiments.
    Figure Legend Snippet: Exosomal miR-155-5p promotes cervical cancer progression via the ARID2-ERCC5-NF-κB signaling axis. (A) Volcano plot analysis of differentially expressed genes (fold change > 4; P < 0.05) after ARID2 knockdown. (B) Pathway network of differentially expressed genes. (C) Coexpression network of differentially expressed genes. (D) Immunoblotting assays of the indicated proteins in CaSki cells with the indicated treatments. (E, F) We used molecular docking to predict whether ARID2 and ERCC5 could bind. The predicted results show that ARID2 and ERCC5 bound by multiple potential interactions. Furthermore, we determined that ARID2 and ERCC5 bind to each other in cells by co-IP experiments.

    Techniques Used: Western Blot, Co-Immunoprecipitation Assay

    rabbit anti arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc rabbit anti arid2
    Interactions between THRB and pBAF components in THRB-FLAG HepG2 cells. (A) Experimental design to identify THRB-binding proteins by immunoprecipitation with anti-FLAG antibody in THRB-FLAG HepG2 cells followed by mass-spectrometry and IP-Western blotting analysis. (B) Identification of high confidence nuclear proteins co-immunoprecipitated with THRB-FLAB ( P <0.01). (C) Control THRB-FLAG HepG2 cells or cells treated with 3 nM T3 for 1 day were lysed and subjected to anti-FLAG immunoprecipitation and Western blotting with pBAF components PBRM1 and <t>ARID2.</t>
    Rabbit Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "A nuclear receptor facilitates differentiation of human PSCs into more mature hepatocytes"

    Article Title: A nuclear receptor facilitates differentiation of human PSCs into more mature hepatocytes

    Journal: bioRxiv

    doi: 10.1101/2022.03.24.485641

    Interactions between THRB and pBAF components in THRB-FLAG HepG2 cells. (A) Experimental design to identify THRB-binding proteins by immunoprecipitation with anti-FLAG antibody in THRB-FLAG HepG2 cells followed by mass-spectrometry and IP-Western blotting analysis. (B) Identification of high confidence nuclear proteins co-immunoprecipitated with THRB-FLAB ( P <0.01). (C) Control THRB-FLAG HepG2 cells or cells treated with 3 nM T3 for 1 day were lysed and subjected to anti-FLAG immunoprecipitation and Western blotting with pBAF components PBRM1 and ARID2.
    Figure Legend Snippet: Interactions between THRB and pBAF components in THRB-FLAG HepG2 cells. (A) Experimental design to identify THRB-binding proteins by immunoprecipitation with anti-FLAG antibody in THRB-FLAG HepG2 cells followed by mass-spectrometry and IP-Western blotting analysis. (B) Identification of high confidence nuclear proteins co-immunoprecipitated with THRB-FLAB ( P <0.01). (C) Control THRB-FLAG HepG2 cells or cells treated with 3 nM T3 for 1 day were lysed and subjected to anti-FLAG immunoprecipitation and Western blotting with pBAF components PBRM1 and ARID2.

    Techniques Used: Binding Assay, Immunoprecipitation, Mass Spectrometry, Western Blot

    anti arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti arid2
    Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    anti arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti arid2
    Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    anti arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc anti arid2
    A DU-145/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for PBRM1, <t>ARID2,</t> and BRD7 mRNA levels by qRT-PCR using primers listed in Supplementary Table . The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for vehicle-treated cells (assigned a value of 1). B Lysates from DU-145/tet-CshRNA and DU-145/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. C Lysates from DU-145/CsgRNA, DU-145/MUC1sgRNA#1, and DU-145/MUC1sgRNA#2 cells were immunoblotted with antibodies against the indicated proteins. D LNCaP-AI/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for PBRM1, ARID2, and BRD7 mRNA levels by qRT-PCR. The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for vehicle-treated cells (assigned a value of 1). E LNCaP-AI/tet-CshRNA and LNCaP-AI/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. F Lysates from LNCaP/tet-MUC1-C cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. G Lysates from NCI-H660/CshRNA and NCI-H660/MUC1shRNA cells were immunoblotted with antibodies against the indicated proteins.
    Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells"

    Article Title: MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells

    Journal: Oncogene

    doi: 10.1038/s41388-021-01899-y

    A DU-145/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for PBRM1, ARID2, and BRD7 mRNA levels by qRT-PCR using primers listed in Supplementary Table . The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for vehicle-treated cells (assigned a value of 1). B Lysates from DU-145/tet-CshRNA and DU-145/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. C Lysates from DU-145/CsgRNA, DU-145/MUC1sgRNA#1, and DU-145/MUC1sgRNA#2 cells were immunoblotted with antibodies against the indicated proteins. D LNCaP-AI/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for PBRM1, ARID2, and BRD7 mRNA levels by qRT-PCR. The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for vehicle-treated cells (assigned a value of 1). E LNCaP-AI/tet-CshRNA and LNCaP-AI/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. F Lysates from LNCaP/tet-MUC1-C cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. G Lysates from NCI-H660/CshRNA and NCI-H660/MUC1shRNA cells were immunoblotted with antibodies against the indicated proteins.
    Figure Legend Snippet: A DU-145/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for PBRM1, ARID2, and BRD7 mRNA levels by qRT-PCR using primers listed in Supplementary Table . The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for vehicle-treated cells (assigned a value of 1). B Lysates from DU-145/tet-CshRNA and DU-145/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. C Lysates from DU-145/CsgRNA, DU-145/MUC1sgRNA#1, and DU-145/MUC1sgRNA#2 cells were immunoblotted with antibodies against the indicated proteins. D LNCaP-AI/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were analyzed for PBRM1, ARID2, and BRD7 mRNA levels by qRT-PCR. The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for vehicle-treated cells (assigned a value of 1). E LNCaP-AI/tet-CshRNA and LNCaP-AI/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. F Lysates from LNCaP/tet-MUC1-C cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. G Lysates from NCI-H660/CshRNA and NCI-H660/MUC1shRNA cells were immunoblotted with antibodies against the indicated proteins.

    Techniques Used: Quantitative RT-PCR

    A Schemas of the ARID2 and BRD7 promoter regions with positioning of putative E2F binding motifs. B , C Soluble chromatin from DU-145 cells was precipitated with anti-E2F1, anti-MUC1-C or a control IgG (left). Soluble chromatin was precipitated with anti-MUC1-C (ChIP) and then reprecipitated with anti-E2F1 or a control IgG (re-ChIP) (right). The DNA samples were amplified by qPCR with primers for the ARID2 ( B ) and BRD7 ( C ) promoter regions. The results (mean ± SD of 3 determinations) are expressed as the relative fold enrichment compared to that obtained with the IgG control (assigned a value of 1). D , E DU-145/tet-MUC1shRNA cells were treated with vehicle or DOX for 7 days. Soluble chromatin was precipitated with anti-E2F1 or a control IgG. The DNA samples were amplified by qPCR with primers for the PBRM1 ( D ) and BRD7 ( E ) promoter regions. The results (mean ± SD of 3 determinations) are expressed as the relative fold enrichment compared to that obtained with the IgG control (assigned a value of 1). F DU-145/CshRNA and DU-145/E2F1shRNA cells were analyzed for ARID2 and BRD7 mRNA levels by qRT-PCR. The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for CshRNA cells (assigned a value of 1). G Lysates from DU-145/CshRNA and DU-145/E2F1shRNA (left) or LNCaP-AI/CshRNA and LNCaP-AI/E2F1shRNA (right) cells were immunoblotted with antibodies against the indicated proteins.
    Figure Legend Snippet: A Schemas of the ARID2 and BRD7 promoter regions with positioning of putative E2F binding motifs. B , C Soluble chromatin from DU-145 cells was precipitated with anti-E2F1, anti-MUC1-C or a control IgG (left). Soluble chromatin was precipitated with anti-MUC1-C (ChIP) and then reprecipitated with anti-E2F1 or a control IgG (re-ChIP) (right). The DNA samples were amplified by qPCR with primers for the ARID2 ( B ) and BRD7 ( C ) promoter regions. The results (mean ± SD of 3 determinations) are expressed as the relative fold enrichment compared to that obtained with the IgG control (assigned a value of 1). D , E DU-145/tet-MUC1shRNA cells were treated with vehicle or DOX for 7 days. Soluble chromatin was precipitated with anti-E2F1 or a control IgG. The DNA samples were amplified by qPCR with primers for the PBRM1 ( D ) and BRD7 ( E ) promoter regions. The results (mean ± SD of 3 determinations) are expressed as the relative fold enrichment compared to that obtained with the IgG control (assigned a value of 1). F DU-145/CshRNA and DU-145/E2F1shRNA cells were analyzed for ARID2 and BRD7 mRNA levels by qRT-PCR. The results (mean ± SD of 4 determinations) are expressed as relative mRNA levels compared to that obtained for CshRNA cells (assigned a value of 1). G Lysates from DU-145/CshRNA and DU-145/E2F1shRNA (left) or LNCaP-AI/CshRNA and LNCaP-AI/E2F1shRNA (right) cells were immunoblotted with antibodies against the indicated proteins.

    Techniques Used: Binding Assay, Amplification, Quantitative RT-PCR

    A Lysates from DU-145/CshRNA and DU-145/ARID1AshRNA (left) or DU-145/CshRNA and DU-145/PBRM1shRNA (right) cells were immunoblotted with antibodies against the indicated proteins. B Lysates from DU-145/CshRNA and DU-145/BRG1shRNA (left) or DU-145/CshRNA and DU-145/ARID1AshRNA (right) cells were immunoblotted with antibodies against the indicated proteins. C Lysates from DU-145/CshRNA and DU-145/PBRM1shRNA cells were immunoblotted with antibodies against the indicated proteins. D Lysates from DU-145/CshRNA and DU-145/ARID1A (left) or DU-145/CshRNA and DU-145/PBRM1shRNA (right) cells were immunoblotted with antibodies against the indicated proteins. E DU-145/CshRNA and DU-145/PBRM1shRNA cells were assayed for tumorsphere formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as relative tumorsphere number per field compared to the CshRNA control (assigned a value of 1) (right). Scale bar: 100 microns. F MUC1-C integrates activation of the esBAF and PBAF chromatin remodeling pathways in CRPC/NEPC progression. The MUC1-C cytoplasmic domain binds directly to the E2F1 DNA binding domain to activate expression of BRG1 and components of the esBAF and PBAF (PBRM1, ARID2, and BRD7) complexes. The MUC1-C→E2F1→esBAF/ARID1A pathway induces EMT and expression of NOTCH1, NANOG, and MYC. The present results demonstrate that the MUC1-C→E2F1→PBAF/PBRM1 pathway induces NRF2-mediated redox balance and expression of OSKM + NANOG. MUC1-C→E2F1→BRG1 signaling integrates cross-talk between the esBAF and PBAF pathways to drive the PC CSC state.
    Figure Legend Snippet: A Lysates from DU-145/CshRNA and DU-145/ARID1AshRNA (left) or DU-145/CshRNA and DU-145/PBRM1shRNA (right) cells were immunoblotted with antibodies against the indicated proteins. B Lysates from DU-145/CshRNA and DU-145/BRG1shRNA (left) or DU-145/CshRNA and DU-145/ARID1AshRNA (right) cells were immunoblotted with antibodies against the indicated proteins. C Lysates from DU-145/CshRNA and DU-145/PBRM1shRNA cells were immunoblotted with antibodies against the indicated proteins. D Lysates from DU-145/CshRNA and DU-145/ARID1A (left) or DU-145/CshRNA and DU-145/PBRM1shRNA (right) cells were immunoblotted with antibodies against the indicated proteins. E DU-145/CshRNA and DU-145/PBRM1shRNA cells were assayed for tumorsphere formation (left). The results (mean ± SD of 3 biologic replicates) are expressed as relative tumorsphere number per field compared to the CshRNA control (assigned a value of 1) (right). Scale bar: 100 microns. F MUC1-C integrates activation of the esBAF and PBAF chromatin remodeling pathways in CRPC/NEPC progression. The MUC1-C cytoplasmic domain binds directly to the E2F1 DNA binding domain to activate expression of BRG1 and components of the esBAF and PBAF (PBRM1, ARID2, and BRD7) complexes. The MUC1-C→E2F1→esBAF/ARID1A pathway induces EMT and expression of NOTCH1, NANOG, and MYC. The present results demonstrate that the MUC1-C→E2F1→PBAF/PBRM1 pathway induces NRF2-mediated redox balance and expression of OSKM + NANOG. MUC1-C→E2F1→BRG1 signaling integrates cross-talk between the esBAF and PBAF pathways to drive the PC CSC state.

    Techniques Used: Activation Assay, Binding Assay, Expressing

    arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc arid2
    Expression levels of mir-922 and <t> ARID2 </t> in patients with hepatocellular carcinoma.
    Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells"

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    Journal: Oncology Reports

    doi: 10.3892/or.2021.8030

    Expression levels of mir-922 and  ARID2  in patients with hepatocellular carcinoma.
    Figure Legend Snippet: Expression levels of mir-922 and ARID2 in patients with hepatocellular carcinoma.

    Techniques Used: Expressing

    ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.
    Figure Legend Snippet: ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Clone Assay, Luciferase, Plasmid Preparation, Reporter Gene Assay, Transfection, Immunoprecipitation, Activity Assay, Agarose Gel Electrophoresis, Mutagenesis, Negative Control

    Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.
    Figure Legend Snippet: Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.

    Techniques Used: Expressing, Cell Counting, Flow Cytometry, Transwell Assay, Migration, Negative Control, Over Expression

    Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.
    Figure Legend Snippet: Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.

    Techniques Used: Expressing, Injection, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Negative Control, Over Expression

    Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.
    Figure Legend Snippet: Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.

    Techniques Used: Expressing, Stable Transfection, Transfection, Plasmid Preparation, shRNA, Cell Counting, Flow Cytometry, Colony Assay, Transwell Assay, Negative Control, Over Expression

    fign  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc fign
    <t>ARID2</t> is a potential target of miR-922 in liver cancer. Relative levels of <t>FIGN</t> and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.
    Fign, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fign/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    fign - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells"

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    Journal: Oncology Reports

    doi: 10.3892/or.2021.8030

    ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.
    Figure Legend Snippet: ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Clone Assay, Luciferase, Plasmid Preparation, Reporter Gene Assay, Transfection, Immunoprecipitation, Activity Assay, Agarose Gel Electrophoresis, Mutagenesis, Negative Control

    arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc arid2
    Expression levels of mir-922 and <t> ARID2 </t> in patients with hepatocellular carcinoma.
    Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells"

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    Journal: Oncology Reports

    doi: 10.3892/or.2021.8030

    Expression levels of mir-922 and  ARID2  in patients with hepatocellular carcinoma.
    Figure Legend Snippet: Expression levels of mir-922 and ARID2 in patients with hepatocellular carcinoma.

    Techniques Used: Expressing

    ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.
    Figure Legend Snippet: ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Clone Assay, Luciferase, Plasmid Preparation, Reporter Gene Assay, Transfection, Immunoprecipitation, Activity Assay, Agarose Gel Electrophoresis, Mutagenesis, Negative Control

    Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.
    Figure Legend Snippet: Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.

    Techniques Used: Expressing, Cell Counting, Flow Cytometry, Transwell Assay, Migration, Negative Control, Over Expression

    Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.
    Figure Legend Snippet: Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.

    Techniques Used: Expressing, Injection, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Negative Control, Over Expression

    Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.
    Figure Legend Snippet: Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.

    Techniques Used: Expressing, Stable Transfection, Transfection, Plasmid Preparation, shRNA, Cell Counting, Flow Cytometry, Colony Assay, Transwell Assay, Negative Control, Over Expression

    arid2 antibody  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc arid2 antibody
    Expression levels of mir-922 and <t> ARID2 </t> in patients with hepatocellular carcinoma.
    Arid2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/arid2 antibody/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    arid2 antibody - by Bioz Stars, 2023-02
    94/100 stars

    Images

    1) Product Images from "CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells"

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    Journal: Oncology Reports

    doi: 10.3892/or.2021.8030

    Expression levels of mir-922 and  ARID2  in patients with hepatocellular carcinoma.
    Figure Legend Snippet: Expression levels of mir-922 and ARID2 in patients with hepatocellular carcinoma.

    Techniques Used: Expressing

    ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.
    Figure Legend Snippet: ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Clone Assay, Luciferase, Plasmid Preparation, Reporter Gene Assay, Transfection, Immunoprecipitation, Activity Assay, Agarose Gel Electrophoresis, Mutagenesis, Negative Control

    Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.
    Figure Legend Snippet: Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.

    Techniques Used: Expressing, Cell Counting, Flow Cytometry, Transwell Assay, Migration, Negative Control, Over Expression

    Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.
    Figure Legend Snippet: Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.

    Techniques Used: Expressing, Injection, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Negative Control, Over Expression

    Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.
    Figure Legend Snippet: Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.

    Techniques Used: Expressing, Stable Transfection, Transfection, Plasmid Preparation, shRNA, Cell Counting, Flow Cytometry, Colony Assay, Transwell Assay, Negative Control, Over Expression

    arid2  (Cell Signaling Technology Inc)


    Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Cell Signaling Technology Inc arid2
    Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    arid2 - by Bioz Stars, 2023-02
    94/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Cell Signaling Technology Inc anti arid2
    <t>ARID2</t> is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.
    Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti arid2 - by Bioz Stars, 2023-02
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc rabbit anti arid2
    Interactions between THRB and pBAF components in THRB-FLAG HepG2 cells. (A) Experimental design to identify THRB-binding proteins by immunoprecipitation with anti-FLAG antibody in THRB-FLAG HepG2 cells followed by mass-spectrometry and IP-Western blotting analysis. (B) Identification of high confidence nuclear proteins co-immunoprecipitated with THRB-FLAB ( P <0.01). (C) Control THRB-FLAG HepG2 cells or cells treated with 3 nM T3 for 1 day were lysed and subjected to anti-FLAG immunoprecipitation and Western blotting with pBAF components PBRM1 and <t>ARID2.</t>
    Rabbit Anti Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti arid2 - by Bioz Stars, 2023-02
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc arid2
    Expression levels of mir-922 and <t> ARID2 </t> in patients with hepatocellular carcinoma.
    Arid2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/arid2/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    arid2 - by Bioz Stars, 2023-02
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc fign
    <t>ARID2</t> is a potential target of miR-922 in liver cancer. Relative levels of <t>FIGN</t> and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.
    Fign, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fign/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    fign - by Bioz Stars, 2023-02
    94/100 stars
      Buy from Supplier

    94
    Cell Signaling Technology Inc arid2 antibody
    Expression levels of mir-922 and <t> ARID2 </t> in patients with hepatocellular carcinoma.
    Arid2 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/arid2 antibody/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    arid2 antibody - by Bioz Stars, 2023-02
    94/100 stars
      Buy from Supplier

    Image Search Results


    ARID2 is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.

    Journal: International Journal of Biological Sciences

    Article Title: HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer

    doi: 10.7150/ijbs.38146

    Figure Lengend Snippet: ARID2 is a direct downstream target of miR-155-5p in cervical cancer progression. (A) Target gene prediction for miR-1247-3p with two bioinformatics tools. (B) qRT-PCR and western blot assays of ARID2 expression in CaSki cells treated with miR-155-5p mimic or normal control. (C) The wild-type and a mutated type of the binding site between miR-155-5p and ARID2 3ʹ-UTR. (D) Relative luciferase activity of CaSki cells in the presence of the indicated treatments (E, F) Migration assay and qRT-PCR analysis of CaSki cells transfected with ARID2-specific siRNAs or control. (G) The effect of miR-155-5p on the migration ability of CaSki cells overexpressing ARID2.

    Article Snippet: The primary antibodies and dilutions were as follows: anti-ARID2 (1:1000, Cell Signaling Technology, USA), anti-CD63, anti-CD9, anti-p-ERCC5, anti-CD81, anti-p-NF-KB, and anti-NF-KB (1:500, Proteintech, USA).

    Techniques: Quantitative RT-PCR, Western Blot, Expressing, Binding Assay, Luciferase, Activity Assay, Migration, Transfection

    Exosomal miR-155-5p promotes cervical cancer progression via the ARID2-ERCC5-NF-κB signaling axis. (A) Volcano plot analysis of differentially expressed genes (fold change > 4; P < 0.05) after ARID2 knockdown. (B) Pathway network of differentially expressed genes. (C) Coexpression network of differentially expressed genes. (D) Immunoblotting assays of the indicated proteins in CaSki cells with the indicated treatments. (E, F) We used molecular docking to predict whether ARID2 and ERCC5 could bind. The predicted results show that ARID2 and ERCC5 bound by multiple potential interactions. Furthermore, we determined that ARID2 and ERCC5 bind to each other in cells by co-IP experiments.

    Journal: International Journal of Biological Sciences

    Article Title: HIV-1-infected cell-derived exosomes promote the growth and progression of cervical cancer

    doi: 10.7150/ijbs.38146

    Figure Lengend Snippet: Exosomal miR-155-5p promotes cervical cancer progression via the ARID2-ERCC5-NF-κB signaling axis. (A) Volcano plot analysis of differentially expressed genes (fold change > 4; P < 0.05) after ARID2 knockdown. (B) Pathway network of differentially expressed genes. (C) Coexpression network of differentially expressed genes. (D) Immunoblotting assays of the indicated proteins in CaSki cells with the indicated treatments. (E, F) We used molecular docking to predict whether ARID2 and ERCC5 could bind. The predicted results show that ARID2 and ERCC5 bound by multiple potential interactions. Furthermore, we determined that ARID2 and ERCC5 bind to each other in cells by co-IP experiments.

    Article Snippet: The primary antibodies and dilutions were as follows: anti-ARID2 (1:1000, Cell Signaling Technology, USA), anti-CD63, anti-CD9, anti-p-ERCC5, anti-CD81, anti-p-NF-KB, and anti-NF-KB (1:500, Proteintech, USA).

    Techniques: Western Blot, Co-Immunoprecipitation Assay

    Interactions between THRB and pBAF components in THRB-FLAG HepG2 cells. (A) Experimental design to identify THRB-binding proteins by immunoprecipitation with anti-FLAG antibody in THRB-FLAG HepG2 cells followed by mass-spectrometry and IP-Western blotting analysis. (B) Identification of high confidence nuclear proteins co-immunoprecipitated with THRB-FLAB ( P <0.01). (C) Control THRB-FLAG HepG2 cells or cells treated with 3 nM T3 for 1 day were lysed and subjected to anti-FLAG immunoprecipitation and Western blotting with pBAF components PBRM1 and ARID2.

    Journal: bioRxiv

    Article Title: A nuclear receptor facilitates differentiation of human PSCs into more mature hepatocytes

    doi: 10.1101/2022.03.24.485641

    Figure Lengend Snippet: Interactions between THRB and pBAF components in THRB-FLAG HepG2 cells. (A) Experimental design to identify THRB-binding proteins by immunoprecipitation with anti-FLAG antibody in THRB-FLAG HepG2 cells followed by mass-spectrometry and IP-Western blotting analysis. (B) Identification of high confidence nuclear proteins co-immunoprecipitated with THRB-FLAB ( P <0.01). (C) Control THRB-FLAG HepG2 cells or cells treated with 3 nM T3 for 1 day were lysed and subjected to anti-FLAG immunoprecipitation and Western blotting with pBAF components PBRM1 and ARID2.

    Article Snippet: Western blotting was performed with a rabbit anti-PBRM1 antibody (Bethyl Laboratories A301-591A, 1:2000), a rabbit anti-ARID2 (Cell Signaling Technology 82342S 1:1000), or a mouse anti FLAG antibody (Sigma F1804 1:4000) based on previous methods ( ).

    Techniques: Binding Assay, Immunoprecipitation, Mass Spectrometry, Western Blot

    Expression levels of mir-922 and  ARID2  in patients with hepatocellular carcinoma.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Expression levels of mir-922 and ARID2 in patients with hepatocellular carcinoma.

    Article Snippet: The immunoblot membranes were blocked with 5% fat-free dry milk in TBST (0.1% Tween-20) buffer at 37°C for 2 h and incubated with primary antibodies overnight at 4°C ( ARID2 , 1:1,000, cat. no. #82342, Cell Signaling Technology, Inc.; FIGN, 1:1,000, cat. no. ab122238, Abcam).

    Techniques: Expressing

    ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Article Snippet: The immunoblot membranes were blocked with 5% fat-free dry milk in TBST (0.1% Tween-20) buffer at 37°C for 2 h and incubated with primary antibodies overnight at 4°C ( ARID2 , 1:1,000, cat. no. #82342, Cell Signaling Technology, Inc.; FIGN, 1:1,000, cat. no. ab122238, Abcam).

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Clone Assay, Luciferase, Plasmid Preparation, Reporter Gene Assay, Transfection, Immunoprecipitation, Activity Assay, Agarose Gel Electrophoresis, Mutagenesis, Negative Control

    Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.

    Article Snippet: The immunoblot membranes were blocked with 5% fat-free dry milk in TBST (0.1% Tween-20) buffer at 37°C for 2 h and incubated with primary antibodies overnight at 4°C ( ARID2 , 1:1,000, cat. no. #82342, Cell Signaling Technology, Inc.; FIGN, 1:1,000, cat. no. ab122238, Abcam).

    Techniques: Expressing, Cell Counting, Flow Cytometry, Transwell Assay, Migration, Negative Control, Over Expression

    Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.

    Article Snippet: The immunoblot membranes were blocked with 5% fat-free dry milk in TBST (0.1% Tween-20) buffer at 37°C for 2 h and incubated with primary antibodies overnight at 4°C ( ARID2 , 1:1,000, cat. no. #82342, Cell Signaling Technology, Inc.; FIGN, 1:1,000, cat. no. ab122238, Abcam).

    Techniques: Expressing, Injection, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Negative Control, Over Expression

    Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.

    Article Snippet: The immunoblot membranes were blocked with 5% fat-free dry milk in TBST (0.1% Tween-20) buffer at 37°C for 2 h and incubated with primary antibodies overnight at 4°C ( ARID2 , 1:1,000, cat. no. #82342, Cell Signaling Technology, Inc.; FIGN, 1:1,000, cat. no. ab122238, Abcam).

    Techniques: Expressing, Stable Transfection, Transfection, Plasmid Preparation, shRNA, Cell Counting, Flow Cytometry, Colony Assay, Transwell Assay, Negative Control, Over Expression

    ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Article Snippet: The immunoblot membranes were blocked with 5% fat-free dry milk in TBST (0.1% Tween-20) buffer at 37°C for 2 h and incubated with primary antibodies overnight at 4°C ( ARID2 , 1:1,000, cat. no. #82342, Cell Signaling Technology, Inc.; FIGN, 1:1,000, cat. no. ab122238, Abcam).

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Clone Assay, Luciferase, Plasmid Preparation, Reporter Gene Assay, Transfection, Immunoprecipitation, Activity Assay, Agarose Gel Electrophoresis, Mutagenesis, Negative Control

    Expression levels of mir-922 and  ARID2  in patients with hepatocellular carcinoma.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Expression levels of mir-922 and ARID2 in patients with hepatocellular carcinoma.

    Article Snippet: The supernatants were collected and incubated with ARID2 antibody (1:1,000, cat. no. #82342; Cell Signaling Technology, Inc.) and FIGN antibody (1:1,000, cat. no. ab122238, Abcam); overnight at 4°C.

    Techniques: Expressing

    ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: ARID2 is a potential target of miR-922 in liver cancer. Relative levels of FIGN and ARID2 expression levels in 10 pairs of liver cancer and adjacent non-tumor tissue were determined by reverse transcription-quantitative PCR and western blot analysis. WT or MT 3'UTR of FIGN and ARID2 were cloned into luciferase reporter vector to generate WT or MT FIGN and ARID2 luciferase reporter plasmids, respectively. Luciferase reporter gene assay was performed in MHCC97L cells following transfection with miR-922 mimics and plasmid. The presence of miR-922 in miRNA/AGO2 complex was determined by RNA immunoprecipitation using anti-AGO2 antibody. (A) FIGN and ARID2 mRNA transcripts in liver cancer tissue. FIGN and ARID2 protein expression levels in (B) liver cancer tissue and (C) HepG2, MHCC97H and MHCC97L and non-tumor hepatocyte THLE-2 cells. (D) Luciferase activity. (E) Representative images of agarose gel electrophoresis of PCR products. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. C, cancer tissue; P, para-carcinoma tissue; ARID2 , AT-rich interactive domain 2; miR, microRNA; FIGN, fidgetin, microtubule severing factor; WT, wild-type; MT, mutant; NC, negative control; ns, not significant.

    Article Snippet: The supernatants were collected and incubated with ARID2 antibody (1:1,000, cat. no. #82342; Cell Signaling Technology, Inc.) and FIGN antibody (1:1,000, cat. no. ab122238, Abcam); overnight at 4°C.

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Clone Assay, Luciferase, Plasmid Preparation, Reporter Gene Assay, Transfection, Immunoprecipitation, Activity Assay, Agarose Gel Electrophoresis, Mutagenesis, Negative Control

    Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Altered ARID2 expression changes malignant behavior of liver cancer cells. The proliferation, clonogenicity, apoptosis, wound healing and invasion of HepG2 cells were determined following altered ARID2 expression. (A) Cell Counting Kit-8 assay determined cell proliferation. (Bi and Bii) Flow cytometry analysis of apoptotic cells. (Ci and Cii) Cell clonogenicity of HepG2 cells. (Di and Dii) Transwell assay analysis of HepG2 cell invasion. (Ei and Eii) Wound healing analysis of HepG2 cell proliferation and migration. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2 , AT-rich interactive domain 2; OD, optical density; NC, negative control; sh, short hairpin; OE, overexpression.

    Article Snippet: The supernatants were collected and incubated with ARID2 antibody (1:1,000, cat. no. #82342; Cell Signaling Technology, Inc.) and FIGN antibody (1:1,000, cat. no. ab122238, Abcam); overnight at 4°C.

    Techniques: Expressing, Cell Counting, Flow Cytometry, Transwell Assay, Migration, Negative Control, Over Expression

    Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Altered ARID2 expression modulates the growth of xenograft liver cancer tumor in mice. Male Balb/c nude mice were injected subcutaneously with 1×10 7 cells; 28 days later, tumor tissue was dissected and volume and weight were measured. The relative levels of miR-922 expression in tumor tissue were determined by reverse transcription-quantitative PCR and the levels of serum VEGF and TNF-α in mice were measured by ELISA. ARID2 , Bcl-2, Bax, PCNA, Cyclin D1, MMP3 and MMP9 expression levels in tumor tissue were characterized by immunohistochemistry. (A) Tumor-bearing mice. Tumor (B) volume and (C) weight. (D) Relative levels of miR-922 transcripts in tumor tissue. ELISA analysis of serum (E) VEGF and (F) TNF-α levels in mice. (G) Immunohistochemistry analysis of ARID2 , Bcl-2, Bax, PCNA, cyclin D1, MMP3 and MMP9 expression levels in tumor tissue. Data are presented as the mean ± SD (n=3). *P<0.05, ***P<0.001. ARID2, ARID2 , AT-rich interactive domain 2; PCNA, proliferating cell nuclear antigen; CON, control; NC, negative control; sh, short hairpin; OE, over-expression.

    Article Snippet: The supernatants were collected and incubated with ARID2 antibody (1:1,000, cat. no. #82342; Cell Signaling Technology, Inc.) and FIGN antibody (1:1,000, cat. no. ab122238, Abcam); overnight at 4°C.

    Techniques: Expressing, Injection, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Negative Control, Over Expression

    Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.

    Journal: Oncology Reports

    Article Title: CREB1 acts via the miR-922/ ARID2 axis to enhance malignant behavior of liver cancer cells

    doi: 10.3892/or.2021.8030

    Figure Lengend Snippet: Altered ARID2 expression modulates miR-922 inhibitor-decreased malignant behavior of HepG2 cells. HepG2 cells were stably transfected with miR-922 inhibitor and transfected with plasmid for ARID2 expression or ARID2 -specific shRNA for ARID2 silencing. Control cells were transfected with vehicle. (A) Cell Counting Kit-8 determined cell proliferation. (Bi and Bii) Number of apoptotic HepG2 cells was analyzed by flow cytometry. (Ci and Cii) Clonogenicity of each group of HepG2 cells was analyzed by colony formation assay. (Di and Dii) Wound healing analysis of each group of HepG2 cells. (Ei and Eii) Transwell assay analysis determined the invasion of each group of HepG2 cells. Data are presented as the mean ± SD (n=3). *P<0.05, **P<0.01, ***P<0.001. ARID2 , AT-rich interactive domain 2; miR, microRNA; sh, short hairpin; OD, optical density; NC, negative control; OE, over-expression.

    Article Snippet: The supernatants were collected and incubated with ARID2 antibody (1:1,000, cat. no. #82342; Cell Signaling Technology, Inc.) and FIGN antibody (1:1,000, cat. no. ab122238, Abcam); overnight at 4°C.

    Techniques: Expressing, Stable Transfection, Transfection, Plasmid Preparation, shRNA, Cell Counting, Flow Cytometry, Colony Assay, Transwell Assay, Negative Control, Over Expression